Remission induction in a Jehovah's witness patient with acute myeloid leukaemia using gemtuzumab ozogamicin.
A 40-year-old patient, who was a Jehovah's Witness, with acute myeloid leukaemia entered remission using a chemotherapeutic based regime aided by the addition of gemtuzumab ozogamicin without requiring any blood product support. The use of gemtuzumab ozogamicin may have helped avoid fatal pancytopenia. The use of gemtuzumab ozogamicin might be considered in similar situations.
Bareford
D
D
Department Haematology, City Hospital, Birmingham, UK. d.bareford@bham.ac.uk
Odeh
B
B
Narayanan
S
S
Wiltshire
S
S
D000328:Adult; D000617:Aminoglycosides / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000079982:Gemtuzumab; D006801:Humans; D033221:Jehovah's Witnesses; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D012074:Remission Induction
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000079982:Gemtuzumab